Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: Results from a dose-finding clinical trial in older adults

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 2, 2012, Pages 216-227

  Della Cioppa, Giovanni ^a   Nicolay, Uwe ^a   Lindert, Kelly ^a   Leroux Roels, Geert ^b   Clement, Frederic ^b   Castellino, Flora ^a   Galli, Grazia ^a   Groth, Nicola ^a   Del Giudice, Giuseppe ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Adjuvant; Dose finding; H3N2; Influenza vaccine; MF59; Trivalent

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FATIGUE; FEMALE; HIP DISLOCATION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; PATIENT MONITORING; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEASONAL INFLUENZA; SIDE EFFECT; SWEATING; VEIN THROMBOSIS; VOMITING;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; POLYSORBATES; SQUALENE; VACCINATION;

EID: 84861818516     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.18445     Document Type: Article

References (44)

1. Fleming DM, Elliot AJ. The impact of influenza on the health and health care utilisation of elderly people. Vaccine 2005; 23(Suppl 1):S1-9; PMID: 15908058; http://dx.doi.org/10.1016/j.vaccine.2005. 04.018
2. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005; 23(Suppl 1):S10-25; PMID:15908062; http://dx.doi.org/10.1016/j.vaccine.2005.04.019
3. Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, Edmunds WJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007; 54:530-8; PMID:17097147; http://dx. doi.org/10.1016/j.jinf.2006. 09.017
4. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; http://dx.doi.org/10.1001/ jama.289.2.179
5. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69; PMID:16213065; http://dx.doi.org/10.1016/j.vaccine.2005.08.105
6. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70: 767-77; PMID:4509641; http://dx.doi.org/10.1017/ S0022172400022610
7. McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, et al. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418-25; PMID:19368783; http://dx.doi.org/10. 1016/j.vaccine. 2009.01.136
8. Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002; 37:427-39; PMID:11772530; http:// dx.doi.org/10.1016/S0531-5565(01)00210-8
9. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35: 69-75; PMID:367490
10. Remarque EJ. Influenza vaccination in elderly people. Exp Gerontol 1999; 34:445-52; PMID:10433399; http://dx.doi.org/10.1016/S0531-5565(99)00007-8
11. Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Corsi MP, et al. The immune system in the elderly: I. Specific humoral immunity. Immunol Res 1999; 20:101-8; PMID:10580635; http://dx.doi.org/ 10.1007/BF02786466
12. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007; 25:3066-9; PMID:17275144; http://dx.doi.org/10.1016/j.vaccine. 2007.01.025
13. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656-63; PMID:17913310; http://dx. doi.org/10.1016/j.vaccine.2007.08.042
14. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80; PMID: 19508159; http://dx.doi.org/10.1086/599790
15. Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7; PMID:16717175; http://dx.doi.org/10.1001/archinte. 166.10.1121
16. Banzhoff A, Nacci P, Podda A. A new MF59- adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49:177-84; PMID:12679609; http://dx.doi.org/ 10.1159/000069172
17. Sindoni D, La Fauci V, Squeri R, Cannavo G, Bacilieri S, Panatto D, et al. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. J Prev Med Hyg 2009; 50:121-6; PMID:20099444
18. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59- adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007; 26:119-27; PMID:18063446; http://dx.doi.org/10.1016/ j.vaccine.2007.10.051
19. Tosh PK, Poland GA. Emerging vaccines for influenza. Expert Opin Emerg Drugs 2008; 13:21-40; PMID: 18321146; http://dx.doi.org/10.1517/14728214.13.1.21
20. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198: 650-8; PMID:18652550; http://dx.doi.org/10.1086/ 590434
21. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28(Suppl 4):D45-53; PMID:20713260; http://dx.doi.org/10.1016/j. vaccine. 2010.08.028
22. Rudenko LG, Arden NH, Grigorieva E, Naychin A, Rekstin A, Klimov AI, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000; 19:308-18; PMID:10930686; http://dx.doi.org/10.1016/S0264-410X(00) 00153-5
23. Treanor JJ, Mattison HR, Dumyati G, Yinnon A, Erb S, O'Brien D, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117:625-33; PMID:1530193
24. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011; 10:447-62; PMID:21506643; http://dx.doi.org/10. 1586/erv.11.23
25. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009; 27:6959-65; PMID:19751689; http://dx.doi.org/10.1016/j.vaccine.2009.08.101
26. U.S. Food and Drug Administration. Press Release (2009). FDA Approves A High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm195483. htm.
27. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009; 4:e4384; PMID:19197383; http://dx.doi.org/10.1371/journal.pone.0004384
28. Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010; 28:840-8; PMID:19835829; http://dx. doi.org/10.1016/j.vaccine.2009.10.019
29. Arguedas A, Soley C, Abdelnour A, Sales V, Lindert K, Cioppa GD, et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 2011; 7; PMID:21285531; http://dx. doi.org/10.4161/hv.7.1.13411
30. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563-71; PMID:19561422; http://dx.doi.org/10. 1097/INF.0b013e31819d6394
31. Cate TR, Rayford Y, Nino D, Winokur P, Brady R, Belshe R, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. Feb 25; 28(9):2076-9.
32. Kilbourne E. Inacitvated Influenza Vaccines. In: Plotkin A MEe, editor. Vaccines. Philadelphia: Saunders; 1994. 565-81.
33. Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002; 191:203-8; PMID:12458361; http://dx.doi.org/10. 1007/s00430-002-0147-9
34. Li R, Fang H, Li Y, Liu Y, Pellegrini M, Podda A. Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects. Immun Ageing 2008; 5:2; PMID:18289372; http://dx. doi.org/10.1186/1742-4933-5-2
35. Tsai T, Brestrich G, Nacci L, Knuf M, Wutzler P, Karvonen A, et al. Hemaglutinin inhibition and microneutralization antibodies in infants and children receiving seasonal trivalent influenza vaccine (TIV) or MF59-adjuvanted TIV (ATIV). Poster presented at the 29th annual European Society for Pediatric Infectious Disease (ESPID) meeting, 7-11 June 2011, The Hague, the Netherlands.
36. Bocharov G, Quiel J, Luzyanina T, Alon H, Chiglintsev E, Chereshnev V, et al. Feedback regulation of proliferation vs. differentiation rates explains the dependence of CD4 T-cell expansion on precursor number. Proc Natl Acad Sci USA 2011; 108:3318-23; PMID:21292990; http://dx.doi.org/10.1073/pnas. 1019706108
37. Quiel J, Caucheteux S, Laurence A, Singh NJ, Bocharov G, Ben-Sasson SZ, et al. Antigen-stimulated CD4 T-cell expansion is inversely and log-linearly related to precursor number. Proc Natl Acad Sci USA 2011; 108:3312-7; PMID:21292989; http://dx.doi. org/10.1073/pnas.1018525108
38. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, et al. Influenza vaccine immunology. Immunol Rev 2011; 239:167-77; PMID:21198671; http://dx.doi.org/10.1111/j.1600-065X.2010.00974.x
39. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009; 106:3877-82; PMID:19237568; http:// dx.doi.org/10.1073/pnas.0813390106
40. Cusick MF, Wang S, Eckels DD. In vitro responses to avian influenza H5 by human CD4 T cells. J Immunol 2009; 183:6432-41; PMID:19841175; http://dx.doi. org/10.4049/jimmunol.0901617
41. Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 2008; 180:1758-68; PMID:18209073
42. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43; PMID:10074505
43. Center for Biological Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Silver Spring, MD: Food and Drug Administration, May 2007.
44. Committee for proprietary medicinal products. Note for guidance on harmonisation of requirements for influenza vaccines. 12 March 1997, CPMP/BWP/214/96. http:// www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003945.pdf.